Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, explains how the Adjuvant immunotherapy trial may be preferable to Adjuvant therapy in Kidney Cancer in the 2018 Oncology Summit in Huntington Beach, CA
Adjuvant Immunotherapy Trial may be preferable to Adjuvant therapy in Kidney Cancer
